Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1994-11-8
|
| pubmed:abstractText |
Bolus/infusional 5-fluorouracil (5-FU) and folinic acid (FA) is reported to be highly active [partial response (PR) = 54%, median survival 18 months] in patients with metastatic colorectal carcinoma (MCCa). To confirm this level of activity, we conducted a retrospective analysis of 95 previously untreated patients with MCCa treated with FA by 2 h i.v. infusion (200 mg m-2) followed by 5-FU bolus/22 h i.v. infusion (300-500 mg m-2) on days 1 and 2 every 2 weeks. Thirty patients also received N-(phosphonacetyl)-L-aspartate (PALA), 250 mg m-2, 24 h prior to 5-FU/FA. In 81 evaluable patients, the response rate was low: PR = 11%, stable disease (SD) = 36% and median survival = 8 months. There was an improvement in survival with increased 5-FU dosage (500 mg m-2) [relative hazard (RH) = 0.38, 95% CI 0.21-0.70], controlled for age, primary site, PALA, liver function and performance status. Good performance status (PS 0 or 1) was also associated with improved survival (RH = 0.21, 95% CI 0.10-0.46). Response, survival and toxicity were not altered by the co-administration of PALA. Bolus/infusional 5-FU (500 mg m-2) and FA was well tolerated. WHO toxicities (grade 3) were: mucositis, 2%; diarrhoea, 14%; nausea and vomiting, 5%. In light of the apparent dose effect, poor response and low toxicity, we recommend that regimes incorporating higher 5-FU dosages are explored and prospectively validated before bolus/infusional 5-FU becomes accepted standard practice.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917933-16590300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917933-1735689,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917933-1911206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917933-2443619,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917933-3263275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917933-3319136,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7917933-6187448
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0007-0920
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
70
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
749-52
|
| pubmed:dateRevised |
2009-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:7917933-Adult,
pubmed-meshheading:7917933-Aged,
pubmed-meshheading:7917933-Aged, 80 and over,
pubmed-meshheading:7917933-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7917933-Colorectal Neoplasms,
pubmed-meshheading:7917933-Dose-Response Relationship, Drug,
pubmed-meshheading:7917933-Drug Administration Schedule,
pubmed-meshheading:7917933-Female,
pubmed-meshheading:7917933-Fluorouracil,
pubmed-meshheading:7917933-Follow-Up Studies,
pubmed-meshheading:7917933-Humans,
pubmed-meshheading:7917933-Infusions, Intravenous,
pubmed-meshheading:7917933-Leucovorin,
pubmed-meshheading:7917933-Male,
pubmed-meshheading:7917933-Middle Aged,
pubmed-meshheading:7917933-Neoplasm Metastasis,
pubmed-meshheading:7917933-Retrospective Studies,
pubmed-meshheading:7917933-Survival Analysis
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?
|
| pubmed:affiliation |
CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, UK.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|